Effects of Quyu Xiaoban capsules on clinical outcomes and platelet activation and aggregation in patients with unstable angina pectoris

Journal of Alternative and Complementary Medicine

Volumn 13, Issue 3, 2007, Pages 369-374

  Liu, Yun Fang ^a   Yu, Hui Ming ^b   Zhang, Cheng ^b   Yang, Rui Xue ^a   Yan, Fang Fang ^a   Liu, Yan ^a   Zhang, Yun ^b   Zhao, Yu Xia ^a  

^a SHANDONG UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHINESE DRUG; CRATAEGUS EXTRACT; CURCUMA ZEDOARIA EXTRACT; ENOXAPARIN; ISOSORBIDE 5 NITRATE; ISOSORBIDE MONONITRATE; METOPROLOL; METOPROLOL TARTRATE; NATURAL PRODUCT; PADGEM PROTEIN; PLACEBO; PLANT EXTRACT; QUYU XIAOBAN; RHEUM PALMATUM EXTRACT; RHUBARB EXTRACT; SARGASSUM PALLIDUM EXTRACT; UNCLASSIFIED DRUG; WHITMANIA PIGRA EXTRACT;

ADULT; ARTICLE; CHINESE MEDICINE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG CAPSULE; ELECTROCARDIOGRAM; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PHYTOTHERAPY; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME;

EID: 34247597244     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2006.6226     Document Type: Article

References (20)

1. Kennon S, Price CP, Mills PG., et al. The central role of platelet activation in determining the severity of acute coronary syndromes. Heart 2003;89:1253-1254.
2. Umman B. Antiplatelet therapy in acute coronary syndromes without ST segment elevation. Anadolu Kardiyol Derg 2006;(Suppl 1):13-19.
3. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
4. Liu YF, Zhao YX, Yu HM. Experimental study on quyu xiaoban capsules for removing atherosclerosis. J Tradit Chin Med 2005;46:777-779.
5. International Cardiology Association and Society and World Health Organization Clinical Denomination Standard Combined Subject Group. Ischemic heart disease denomination and diagnosis criteria. Chin J Cardiol 1981;9:75-76.
6. Yang RX, Zhao YX, Zhu YY. Effect of quyu xiaoban capsule on unstable angina pectoris. Shanghai J Tradit Chin Med 2004;38:22-23.
7. National Pharmacopoeia Committee. Pharmacopoeia of China. Part I. Beijing: Chinese Publishing Company of the Chemical Industry, 2005; 17, 22, 57, 194,208.
8. Zheng XY. Guiding principle of clinical research on Chinese new drugs. 1 ed. Beijing: Chinese Publishing Company of Medical and Pharmaceutical Technique, 2002;69-73.
9. Chen KJ, Liao JZ, Xiao ZX. Research on cardiocerebrovascular diseases. Shanghai: Shanghai Publishing Company of Sciense and Technology, 1998;318-319.
10. Liu YF, Zhao YX, Yu HM, et al. Clinical study on effects of quyu xiaoban capsule on regression of atherosclerosis. Chin J Integr Med 2005;25:499-450.
11. Atalar E, Aytemir K, Haznedaroglu I, et al. Increased plasma levels of soluble selectins in patients with unstable angina. Int J Cardiol 2001;78:69-73.
12. The FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996;347:561-568.
13. Fox KA. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials. Am J Cardiol 1999;84:26M-31M.
14. Turpie AG. Anticoagulants in acute coronary syndromes. Am J Cardiol 1999;84:2M-6M.
15. Parker C 3rd, Vita JA, Freedman JE. Soluble adhesion molecules and unstable coronary artery disease. Atherosclerosis 2001;156:417-424.
16. Hollander JE, Muttreja MR, Dalesandro MR, Shofer FS. Risk stratification of emergency department patients with acute coronary syndromes using P-selectin. J Am Coll Cardiol 1999;34:95-105.
17. Sarma J, Laan CA, Alam S, et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002;105:2166-2171.
18. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
19. Kennon S, Price CP, Mills PG, et al. The central role of platelet activation in determining the severity of acute coronary syndromes. Heart 2003; 89:1253-1254.
20. Chakhtoura EY, Shamoon EF, Haft JI, et al. Comparison of platelet activation in unstable and stable angina pectoris and correlation with coronary angiographic findings. Am J Cardiol 2000;86:835-839.